Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
|
|
GRI BIO, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
4
| Kelly Leanne (CFO) has filed a Form 4 on GRI BIO, Inc.|
Txns:
| Granted 83,333 options to buy
@ $1.52, valued at
$126.7k
|
|
| 08/14/2023 |
4
| Szekeres David Leslie (Director) has filed a Form 4 on GRI BIO, Inc.|
Txns:
| Granted 34,483 options to buy
@ $2.9, valued at
$100k
|
|
| 08/14/2023 |
4
| SIMPSON CAMILLA V (Director) has filed a Form 4 on GRI BIO, Inc.|
Txns:
| Granted 34,483 options to buy
@ $2.9, valued at
$100k
|
|
| 08/14/2023 |
4
| Rongen Roelof (Director) has filed a Form 4 on GRI BIO, Inc.|
Txns:
| Granted 34,483 options to buy
@ $2.9, valued at
$100k
|
|
| 08/14/2023 |
4
| Baker David Charles (Director) has filed a Form 4 on GRI BIO, Inc.|
Txns:
| Granted 34,483 options to buy
@ $2.9, valued at
$100k
|
|
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2022 |
4
| Thorell Marella (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Disposed of 28,517 shares
@ $0 |
|
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Ammer Richard (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 7,500 options to buy
@ $0.51, valued at
$3.8k
|
|
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2022 |
4
| Baker David Charles (CEO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 61,000 options to buy
@ $5.63, valued at
$343.4k
|
|
| 03/01/2022 |
4
| Kelly Leanne M. (CFO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 50,000 options to buy
@ $5.63, valued at
$281.5k
|
|
| 06/04/2021 |
4
| Kelly Leanne M. (CFO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Bought 3,657 shares
@ $4, valued at
$14.6k
Bought 1,085 shares
@ $4.05, valued at
$4.4k
Bought 1,508 shares
@ $4.08, valued at
$6.2k
|
|
| 05/27/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Ammer Richard (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $3.66, valued at
$54.9k
Granted 10,204 options to buy
@ $3.66, valued at
$37.3k
|
|
| 05/18/2021 |
4
| Levi Ofir (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $3.66, valued at
$54.9k
Granted 30,000 options to buy
@ $3.66, valued at
$109.8k
|
|
| 05/18/2021 |
4
| Kelly Leanne M. (CFO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 70,000 options to buy
@ $3.66, valued at
$256.2k
|
|
| 05/18/2021 |
4
| Toren Penny (SVP, Regul Affairs & Prog Mgmt) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $3.66, valued at
$91.5k
|
|
| 05/18/2021 |
4
| Baker David Charles (CEO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 options to buy
@ $3.66, valued at
$366k
|
|
| 02/12/2021 |
4
| Ammer Richard (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Acquired 47,063 shares
@ $6.4, valued at
$301.2k
|
|
| 02/12/2021 |
4
| SALMON Pharma GmbH (10% Owner) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Acquired 47,063 shares
@ $6.4, valued at
$301.2k
|
|
| 02/12/2021 |
4
| Thorell Marella (Director) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $8, valued at
$120k
|
|
| 02/12/2021 |
4
| Baker David Charles (CEO) has filed a Form 4 on Vallon Pharmaceuticals, Inc.|
Txns:
| Acquired 7,843 shares
@ $6.4, valued at
$50.2k
Bought 1,000 shares
@ $8, valued at
$8k
|
|
|
|